A Quantitative Modeling and Simulation Framework to Support Candidate and Dose Selection of Anti‐SARS‐CoV‐2 Monoclonal Antibodies to Advance Bamlanivimab Into a First‐in‐Human Clinical Trial

Neutralizing monoclonal antibodies (mAb), novel therapeutics for the treatment of coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), have been urgently researched from the start of the pandemic. The selection of the optimal mAb candidate and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chigutsa, Emmanuel, Jordie, Eric, Riggs, Matthew, Nirula, Ajay, Elmokadem, Ahmed, Knab, Tim, Chien, Jenny Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653169/
https://www.ncbi.nlm.nih.gov/pubmed/34687040
http://dx.doi.org/10.1002/cpt.2459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653169/
https://www.ncbi.nlm.nih.gov/pubmed/34687040
http://dx.doi.org/10.1002/cpt.2459

Ejemplares similares